Fig. 3.

Cumulative probability plots for mTSS change from baseline to week 156

Patients are from the long-term extension period population. Missing data were linearly extrapolated if patients had a baseline and ≥1 post-baseline value (i.e. week 52, 108 or 156). At week 52, 0% were imputed, at week 108 1.6% (n = 4) were imputed, and at week 156 10.8% (n = 28) were imputed using linear extrapolation. ADA: adalimumab; IXEQ4W/Q2W: 80 mg ixekizumab every 4 weeks/2 weeks; mTSS: van der Heijde modified total Sharp score; N: total patient number in the long-term extension period population; Nx: number of patients with non-missing change from baseline data after linear extrapolation; PBO: placebo.